TrialBMC infectious diseases2020

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.

Charissa Fay Corazon Borja-Tabora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.